Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Translational Experimental Basis of Indirect Adenosine Receptor Agonist Stimulation for Bone Regeneration: A Review

Ehlen QT., Mirsky NA., Slavin BV., Parra M., Nayak VV., Cronstein B.

Clinical Trial on Face & Skin, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38892291
PMCID
PMC11172580
DOI
10.3390/ijms25116104
Citations
4

Abstract (original English)

Bone regeneration remains a significant clinical challenge, often necessitating surgical approaches when healing bone defects and fracture nonunions. Within this context, the modulation of adenosine signaling pathways has emerged as a promising therapeutic option, encouraging osteoblast activation and tempering osteoclast differentiation. A literature review of the PubMed database with relevant keywords was conducted. The search criteria involved in vitro or in vivo models, with clear methodological descriptions. Only studies that included the use of indirect adenosine agonists, looking at the effects of bone regeneration, were considered relevant according to the eligibility criteria. A total of 29 articles were identified which met the inclusion and exclusion criteria, and they were reviewed to highlight the preclinical translation of adenosine agonists. While preclinical studies demonstrate the therapeutic potential of adenosine signaling in bone regeneration, its clinical application remains unrealized, underscoring the need for further clinical trials. To date, only large, preclinical animal models using indirect adenosine agonists have been successful in stimulating bone regeneration. The adenosine receptors (A 1 , A 2A , A 2B , and A 3 ) stimulate various pathways, inducing different cellular responses. Specifically, indirect adenosine agonists act to increase the extrac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansReceptors, Purinergic P1AdenosineBone RegenerationSignal TransductionPurinergic P1 Receptor AgonistsTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research